Literature DB >> 14746517

Emerging infectious threats to the blood supply.

Roger Y Dodd1, David A Leiby.   

Abstract

During the past 15 years, it has become clear that new agents and new strains of existing agents continue to emerge worldwide as protagonists of infectious disease. These emerging agents pose threats not only to the general human population but also to recipients of blood transfusions. Indeed, the modern era of blood safety perhaps began with the recognition of HIV as an emerging agent transmissible by blood transfusion. Today, emerging infectious agents that pose a threat to the blood supply are not limited to viruses, but include bacterial, protozoan, and prion agents. Preventing the transmission of these new agents by blood transfusion is often problematic, as the available tools may be inadequate. It is certain, however, that new agents will continue to emerge as threats to blood safety and these agents are likely to require novel approaches to prevent their transmission.

Entities:  

Mesh:

Year:  2004        PMID: 14746517     DOI: 10.1146/annurev.med.55.091902.103831

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  15 in total

Review 1.  Current safety of the blood supply in the United States.

Authors:  Roger Y Dodd
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 2.  Economics of pathogen inactivation technology for platelet concentrates in Japan.

Authors:  Ulf Staginnus; Laurence Corash
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  The emergence of chagas disease in the United States and Canada.

Authors:  Louis V Kirchhoff; Richard D Pearson
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

4.  Pathogen Reduction in Blood Products: What's Behind These Techniques?

Authors:  Karin Janetzko; Peter Bugert
Journal:  Transfus Med Hemother       Date:  2011       Impact factor: 3.747

Review 5.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

Review 6.  Development of recombinant hemoglobin-based oxygen carriers.

Authors:  Cornelius L Varnado; Todd L Mollan; Ivan Birukou; Bryan J Z Smith; Douglas P Henderson; John S Olson
Journal:  Antioxid Redox Signal       Date:  2012-11-16       Impact factor: 8.401

Review 7.  Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality.

Authors:  Eleftherios C Vamvakas; Morris A Blajchman
Journal:  Transfus Med Rev       Date:  2010-04

Review 8.  Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Authors:  Leopold Grillberger; Thomas R Kreil; Sonia Nasr; Manfred Reiter
Journal:  Biotechnol J       Date:  2009-02       Impact factor: 4.677

9.  Expression and Purification of Functionally Active Recombinant Human Alpha 1-Antitrypsin in Methylotrophic Yeast Pichia pastoris.

Authors:  Sareh Arjmand; Elham Bidram; Abbas Sahebghadam Lotfi; Mehdi Shamsara; Seyed Javad Mowla
Journal:  Avicenna J Med Biotechnol       Date:  2011-07

10.  Neglected infections of poverty in the United States of America.

Authors:  Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2008-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.